Clinical Trial Update: Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of panitumumab and gemcitabine for pancreatic cancer, using overall survival as the primary endpoint; the study was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Panitumumab (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Cancer of Pancreas, Cancer of the Pancreas | Phase 2 | Status: TERMINATED | Results posted: 2014-01-06